STRATEGIC PARTNERSHIPS
Echo Pharmaceuticals utilizes a clear partnering strategy to support its effort to build a portfolio of pharmaceutical products and drug delivery technologies for large patient populations. The company’s partnering strategy is comprised of two key components:
- Out-license internally developed drugs to commercialization partners worldwide, while retaining rights to market products on its own to select market segments should it elect to do so
- Collaborate with companies looking to utilize Alitra™ delivery technology to enhance their own pharmaceutical products.
Partnership Opportunities
Echo Pharmaceuticals welcomes inquiries from companies interested in working together to develop pharmaceutical products, or to commercialize products developed by Echo.
The following is a list of partnering opportunities currently available with Echo Pharmaceuticals. To learn more, please contact the company’s business development department at busdev@echo-pharma.com.
Development/Commercialization Opportunities
- Namisol® (Alzheimer’s Disease)
- Namisol® (Multiple Sclerosis)
- Namisol® (Chronic Pain)
- Namisol® (other indications)
- Alitra™ (lipophilic API’s)